Advanced, Relapsed Gastric or Gastro-oesophageal Junction Carcinoma
1 clinical trials · Condition
◉ Watch Advanced, Relapsed Gastric or Gastro-oesophageal Junction Carcinoma
| Record | Firm | Date |
|---|---|---|
| Toripalimab Combined With Anlotinib for Patients With Advanced, Relapsed, or Refractory Gastric, or Esophagogastric Junction Cancer (EGJC) (NCT04713059) | The Affiliated Hospital of Qingdao University | 2020-01-01 |
Track Advanced, Relapsed Gastric or Gastro-oesophageal Junction Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.